ATEROSKLEROZ RIVOJLANISHIDA DISLIPIDEMIYA VA UNI STATINLAR YORDAMIDA KORREKSIYA QILISHNING ZAMONAVIY KLINIK YONDASHUVLARI
Keywords:
Kalit so‘zlar. ateroskleroz, dislipidemiya, statinlar, LDL-xolesterin, lipid almashinuvi, GMG-KoA reduktaza, endotelial disfunktsiya, lipidni pasaytiruvchi terapiya, kardiovaskulyar xavf., Keywords: atherosclerosis, dyslipidemia, statins, LDL cholesterol, lipid metabolism, HMG-CoA reductase, endothelial dysfunction, lipid-lowering therapy, cardiovascular risk.Abstract
Annotatsiya. Mazkur maqolada ateroskleroz rivojlanishida dislipidemiyaning patogenetik roli va uni statinlar yordamida korreksiya qilishning zamonaviy klinik yondashuvlari yoritilgan. Dislipidemiya aterosklerotik jarayonning asosiy xavf omillaridan biri bo‘lib, LDL-xolesterin darajasining oshishi tomir devorida lipid to‘planishi va yallig‘lanish jarayonlarini kuchaytiradi. Statinlar HMG-KoA reduktaza fermentini ingibitsiya qilish orqali xolesterin sintezini kamaytiradi, endotelial funksiyani yaxshilaydi va yallig‘lanishga qarshi ta’sir ko‘rsatadi. Maqolada statin terapiyasining samaradorligi, qo‘llash ko‘rsatmalari, xavfsizlik profili hamda klinik amaliyotdagi zamonaviy yondashuvlar tahlil qilingan. Shuningdek, yuqori xavf guruhidagi bemorlarda lipidni pasaytiruvchi terapiyaning individuallashtirilgan strategiyalari muhokama qilingan.
Abstract. This article discusses the pathogenetic role of dyslipidemia in the development of atherosclerosis and modern clinical approaches to its correction using statins. Dyslipidemia is one of the main risk factors of the atherosclerotic process, and an increased level of LDL cholesterol promotes lipid accumulation in the vessel wall and intensifies inflammatory processes. Statins reduce cholesterol synthesis by inhibiting the HMG-CoA reductase enzyme, improve endothelial function, and exert anti-inflammatory effects. The article analyzes the effectiveness of statin therapy, indications for its use, its safety profile, and modern approaches in clinical practice. In addition, individualized strategies of lipid-lowering therapy in patients at high risk are discussed.
